Phil Hogarth

Phil
Hogarth

Animal & Plant Health Agency
Biography

Phil obtained his BSc (Hons) at the University of Plymouth in 1993 where he discovered the delights of immunology & parasites.

He then went on to study Immunoparasitology at the Liverpool School of Tropical Medicine in the lab of Ted Bianco, where he characterised CD4 T cell responses to Onchocerca at a time when it seemd like a new cytokine was being discovered every week. He recieved his PhD in 1997.

Then followed a 4 year foray into fundamental T cell development in the gut at the University of Bristol, before he saw the light and returned to studying T cell responses to infection.

In 2001 he joined AHVLA as it was then known to establish a team developing murine models of bovine TB vaccination. During his tenure at APHA he established the Flow Cytometry Core facility which he still manages, and continues to straddle the line between murine and bovine immunology.

Phil is an active  committee member of the Acid Fast Club- the UK Mycobacterial Forum; and a member of the International Society for Advancement of Cytometry's Biosafety Committee.

Research interests

I am a translational immunologist leading a group studying mucosal immunology of TB, the immune response to vaccination and infection to understand: i) How vaccines generate T cell memory and ii) how this affords protective immunity. The overarching strategy: 'understanding how BCG protects allows design of novel TB vaccines'. Using a murine model of M. bovis, we use techniques such as: 12 colour flow, T cell phenotyping/ sorting, adoptive transfer, to study protective CD4 T cells. we use this tractable model to identify & translate immunological insights of TB vaccination into the bovine host. Such approaches allowed us to develop the 1st antibodies to bovine IL-2 & identify CD4 TEM in cattle. Recent interests include immune responses in the lungs, tissue-resident memory cells & delivery of vaccines to respiratory surfaces. This work is undertaken using a One Health approach, with close collaboration with researchers in the human TB vaccine field.